公开(公告)号：US10188728B2

公开(公告)日：2019-01-29

申请号：US14650355

申请日：2013-10-16

Applicant: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventor： Bin Wang ,  Mohammad F. Kiani ,  Yuan Tang

IPC: A61K9/127 ,  A61K39/395 ,  C07K16/22 ,  C07K16/32 ,  A61K45/06 ,  A61K31/277 ,  A61K31/704 ,  A61K47/69 ,  A61K39/00

Abstract: Provided are compositions, methods and kits for treating cancer comprising targeted liposomes comprising a chemotherapy agent and a sensitizer for the chemotherapy agent, and non-targeted liposomes comprising an anti-angiogenic agent. In some embodiments, the targeted liposomes are immunoliposomes. In further embodiments, the immunoliposomes bind to Her-2/neu, and the composition is for treating breast cancer.

公开(公告)号：US20140186431A1

公开(公告)日：2014-07-03

申请号：US14096449

申请日：2013-12-04

Applicant: Temple University - Of The Commonwealth System of Higher Education

Inventor： Bin Wang ,  Mohammad F. Kiani ,  Yuan Tang

IPC: A61K35/28 ,  A61K38/18 ,  A61K9/127

CPC classification number: A61K35/28 ,  A61K9/0019 ,  A61K9/1271 ,  A61K38/1866 ,  A61K47/6913 ,  A61K2300/00

Abstract: Compositions and kits useful for the treatment of myocardial infarction comprise (i) P-selectin-targeted carriers (e.g., P-selectin-targeted liposomes, quantum dots or biodegradable nanoparticles) comprising VEGF and (ii) MSCs.

Abstract translation: 可用于治疗心肌梗死的组合物和试剂盒包含（i）包含VEGF和（ii）MSC的P-选择蛋白靶向载体（例如P-选择素靶向脂质体，量子点或可生物降解的纳米颗粒）。

公开(公告)号：US20150366993A1

公开(公告)日：2015-12-24

申请号：US14650355

申请日：2013-10-16

Applicant: TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventor： Bin Wang ,  Mohammad F. Kiani ,  Yuan Tang

IPC: A61K47/48 ,  A61K39/395 ,  A61K31/277 ,  A61K9/127 ,  A61K31/704

CPC classification number: A61K39/3955 ,  A61K9/1271 ,  A61K9/1273 ,  A61K31/277 ,  A61K31/704 ,  A61K45/06 ,  A61K47/6913 ,  A61K47/6915 ,  A61K2039/507 ,  C07K16/22 ,  C07K16/32 ,  C07K2317/24 ,  A61K2300/00

Abstract: Provided are compositions, methods and kits for treating cancer comprising targeted liposomes comprising a chemotherapy agent and a sensitizer for the chemotherapy agent, and non-targeted liposomes comprising an anti-angiogenic agent. In some embodiments, the targeted liposomes are immunoliposomes. In further embodiments, the immunoliposomes bind to Her-2/neu, and the composition is for treating breast cancer.

Abstract translation: 提供了用于治疗癌症的组合物，方法和试剂盒，其包含靶向脂质体，其包含用于化疗剂的化疗剂和敏化剂，以及包含抗血管生成剂的非靶向脂质体。 在一些实施方案中，靶向脂质体是免疫脂质体。 在另外的实施方案中，免疫脂质体结合Her-2 / neu，并且该组合物用于治疗乳腺癌。